SLTM

Summary

SLTM (SAFB like transcription modulator, HGNC:20709) is a protein-coding gene on chromosome 15q22.1, encoding SAFB-like transcription modulator (Q9NWH9). When overexpressed, acts as a general inhibitor of transcription that eventually leads to apoptosis. In precision oncology, MET Exon 14 Skipping Mutation confers sensitivity to Tepotinib in Lung Non-small Cell Carcinoma (CIViC Level A); 46 further curated variant–drug associations are listed below.

Enables RNA binding activity. Predicted to be involved in DNA-templated transcription and apoptotic process. Located in nuclear body.

Source: NCBI Gene 79811 — automated summary from GO annotations (Alliance of Genome Resources).

At a glance

• Gene–disease (curated): papillary renal cell carcinoma (Definitive, ClinGen) — +7 more curated relationships
• GWAS associations: 26 (top 5% of genes corpus-wide)
• Clinical variants (ClinVar): 5,104 total — 5 pathogenic, 3 likely-pathogenic (top 1% of genes corpus-wide)
• Regional missense constraint (gnomAD): 1 of 3 regions constrained (≈3% of expected missense variation)
• Expression (HPA): Tissue enhanced — highest in liver, choroid plexus, placenta
• GTEx eGene: eQTL in 9 tissues, sQTL in 1 (q < 0.05)
• Phenotypes (HPO): 30
• ChEMBL bioactivity: 1 clinical-phase molecule tested; no curated mechanism-of-action drug
• Precision-oncology evidence (CIViC): 47 curated variant–drug associations
• Cancer driver (intOGen): activating (oncogene-like) across 7 cancer types (inferred from mutation patterns)
• Dosage sensitivity (ClinGen): haploinsufficiency no evidence, triplosensitivity no evidence
• Constraint (gnomAD): pLI 1.00 (loss-of-function intolerant), LOEUF 0.44 (moderately constrained)
• MANE Select transcript: NM_024755

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20709
Approved symbol	SLTM
Name	SAFB like transcription modulator
Location	15q22.1
Locus type	gene with protein product
Status	Approved
Aliases	Met, FLJ13213
Ensembl gene	ENSG00000137776
Ensembl biotype	protein_coding
OMIM	620992
Entrez	79811

Gene structure

Transcript identifiers

Ensembl transcripts: 58 — 31 protein_coding, 15 nonsense_mediated_decay, 10 retained_intron, 2 protein_coding_CDS_not_defined

MANE Select: ENST00000380516

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 9, TSL 3: 5, TSL 4: 4, TSL 5: 7

ENST00000380516, ENST00000249736, ENST00000432750, ENST00000473359, ENST00000474342, ENST00000480144, ENST00000484498, ENST00000492526, ENST00000493062, ENST00000497088, ENST00000557791, ENST00000557924, ENST00000557950, ENST00000558052, ENST00000558486, ENST00000558734, ENST00000558756, ENST00000559261, ENST00000559305, ENST00000559880, ENST00000560012, ENST00000560494, ENST00000560532, ENST00000560682, ENST00000560695, ENST00000628684, ENST00000872290, ENST00000872291, ENST00000872292, ENST00000872293, ENST00000924222, ENST00000924223, ENST00000924224, ENST00000924225, ENST00000924226, ENST00000924227, ENST00000924228, ENST00000924229, ENST00000924230, ENST00000970319, ENST00000970320, ENST00000970321, ENST00000970322, ENST00000980446, ENST00001012069, ENST00001012070, ENST00001012071, ENST00001012072, ENST00001012073, ENST00001012075, ENST00001012076, ENST00001087877, ENST00001087878, ENST00001099199, ENST00001128804, ENST00001128805, ENST00001128806, ENST00001137404

RefSeq mRNA: 2 — MANE Select: NM_024755 NM_001013843, NM_024755

CCDS: CCDS10168

Canonical transcript exons

ENST00000380516 — 21 exons

Exon	Start	End
ENSE00000884973	58899469	58899937
ENSE00001485310	58933404	58933679
ENSE00001687859	58879050	58880107
ENSE00003463671	58897115	58897233
ENSE00003466208	58893821	58893987
ENSE00003489299	58893279	58893364
ENSE00003507273	58932356	58932443
ENSE00003507749	58912563	58912610
ENSE00003510327	58887226	58887540
ENSE00003519075	58892897	58893060
ENSE00003519754	58898803	58898852
ENSE00003528437	58889430	58889554
ENSE00003544072	58888385	58888555
ENSE00003585086	58916935	58916999
ENSE00003609587	58894090	58894193
ENSE00003625753	58883626	58883786
ENSE00003642846	58913499	58913696
ENSE00003644752	58894433	58894582
ENSE00003648734	58890281	58890461
ENSE00003660603	58901260	58901287
ENSE00003671270	58886975	58887119

Expression profiles

Bgee: expression breadth ubiquitous, 291 present calls, max score 99.24.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 66.4422 / max 2550.8852, expressed in 1824 samples.

Highest expression (Bgee): calcaneal tendon, sural nerve, tibia, lobe of thyroid gland, tonsil.

Genetic regulation across tissues (GTEx eQTL / sQTL)

SLTM is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 9 tissues and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

10 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Cells Cultured fibroblasts	eqtl	9.5e-07	-0.11	15:58903480:G:A
Testis	eqtl	1.9e-06	+0.25	15:58907738:T:G
Adipose Subcutaneous	eqtl	3.3e-04	+0.16	15:58866102:G:A
Artery Tibial	eqtl	6.1e-04	+0.41	15:58884882:G:A
Nerve Tibial	eqtl	6.5e-04	+0.41	15:58932543:A:G
Cells Cultured fibroblasts	sqtl	6.1e-03	-0.83	15:58915548:T:C
Brain Cerebellar Hemisphere	eqtl	1.2e-02	-0.20	15:58815663:T:A
Muscle Skeletal	eqtl	1.4e-02	-0.46	15:59102291:C:A
Esophagus Muscularis	eqtl	1.4e-02	+0.43	15:58884882:G:A
Brain Hypothalamus	eqtl	4.5e-02	-0.20	15:58681506:T:C

FANTOM5 promoters

showing 10 of 12 alternative TSS:

Promoter ID	TPM avg	Samples expressed
150253	41.8694	1818
150255	12.5131	1798
150248	3.4912	1101
150251	2.7113	889
150247	2.2751	844
150254	1.1208	682
150245	0.6233	251
150252	0.5725	325
150246	0.3922	181
150258	0.3668	135

Top tissues by expression

showing 100 of 294 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	99.24	gold quality
sural nerve	UBERON:0015488	98.02	gold quality
tibia	UBERON:0000979	97.64	gold quality
left lobe of thyroid gland	UBERON:0001120	97.32	gold quality
tonsil	UBERON:0002372	97.29	gold quality
right lobe of thyroid gland	UBERON:0001119	97.27	gold quality
monocyte	CL:0000576	97.20	gold quality
skin of abdomen	UBERON:0001416	97.20	gold quality
parietal pleura	UBERON:0002400	97.14	gold quality
mononuclear cell	CL:0000842	97.13	gold quality
thyroid gland	UBERON:0002046	97.13	gold quality
visceral pleura	UBERON:0002401	97.08	gold quality
ventricular zone	UBERON:0003053	97.07	gold quality
leukocyte	CL:0000738	96.97	gold quality
lower esophagus mucosa	UBERON:0035834	96.97	gold quality
pleura	UBERON:0000977	96.96	gold quality
mucosa of stomach	UBERON:0001199	96.93	gold quality
metanephros cortex	UBERON:0010533	96.93	gold quality
skin of leg	UBERON:0001511	96.92	gold quality
palpebral conjunctiva	UBERON:0001812	96.82	gold quality
peripheral nervous system	UBERON:0000010	96.81	gold quality
tibial nerve	UBERON:0001323	96.81	gold quality
colonic epithelium	UBERON:0000397	96.76	gold quality
minor salivary gland	UBERON:0001830	96.75	gold quality
esophagus mucosa	UBERON:0002469	96.69	gold quality
small intestine Peyer’s patch	UBERON:0003454	96.67	gold quality
right uterine tube	UBERON:0001302	96.63	gold quality
vagina	UBERON:0000996	96.56	gold quality
right ovary	UBERON:0002118	96.55	gold quality
body of uterus	UBERON:0009853	96.52	gold quality
rectum	UBERON:0001052	96.48	gold quality
germinal epithelium of ovary	UBERON:0001304	96.46	gold quality
spleen	UBERON:0002106	96.46	gold quality
body of stomach	UBERON:0001161	96.44	gold quality
epithelium of nasopharynx	UBERON:0001951	96.41	gold quality
left ovary	UBERON:0002119	96.41	gold quality
endocervix	UBERON:0000458	96.40	gold quality
nasopharynx	UBERON:0001728	96.39	gold quality
zone of skin	UBERON:0000014	96.38	gold quality
ectocervix	UBERON:0012249	96.38	gold quality
esophagus	UBERON:0001043	96.33	gold quality
mouth mucosa	UBERON:0003729	96.32	gold quality
lymph node	UBERON:0000029	96.30	gold quality
stomach	UBERON:0000945	96.30	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.30	gold quality
corpus callosum	UBERON:0002336	96.29	gold quality
subcutaneous adipose tissue	UBERON:0002190	96.28	gold quality
body of pancreas	UBERON:0001150	96.27	gold quality
transverse colon	UBERON:0001157	96.26	gold quality
saliva-secreting gland	UBERON:0001044	96.25	gold quality
gingival epithelium	UBERON:0001949	96.25	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	96.23	gold quality
adenohypophysis	UBERON:0002196	96.19	gold quality
bone marrow cell	CL:0002092	96.14	gold quality
eye	UBERON:0000970	96.13	gold quality
fundus of stomach	UBERON:0001160	96.13	gold quality
right lung	UBERON:0002167	96.12	gold quality
granulocyte	CL:0000094	96.11	gold quality
omental fat pad	UBERON:0010414	96.11	gold quality
pituitary gland	UBERON:0000007	96.10	gold quality
cerebellar cortex	UBERON:0002129	96.10	gold quality
cerebellar hemisphere	UBERON:0002245	96.10	gold quality
peritoneum	UBERON:0002358	96.10	gold quality
muscle layer of sigmoid colon	UBERON:0035805	96.10	gold quality
adipose tissue of abdominal region	UBERON:0007808	96.09	gold quality
left uterine tube	UBERON:0001303	96.08	gold quality
small intestine	UBERON:0002108	96.08	gold quality
adipose tissue	UBERON:0001013	96.02	gold quality
upper lobe of left lung	UBERON:0008952	96.01	gold quality
vermiform appendix	UBERON:0001154	95.98	gold quality
ganglionic eminence	UBERON:0004023	95.98	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.97	gold quality
esophagus squamous epithelium	UBERON:0006920	95.96	gold quality
lower esophagus	UBERON:0013473	95.96	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	95.93	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.90	gold quality
connective tissue	UBERON:0002384	95.88	gold quality
ovary	UBERON:0000992	95.83	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	95.81	gold quality
adrenal tissue	UBERON:0018303	95.72	gold quality
pancreas	UBERON:0001264	95.68	gold quality
endometrium	UBERON:0001295	95.67	gold quality
cerebellum	UBERON:0002037	95.67	gold quality
prostate gland	UBERON:0002367	95.59	gold quality
spinal cord	UBERON:0002240	95.57	gold quality
mucosa of transverse colon	UBERON:0004991	95.56	gold quality
upper lobe of lung	UBERON:0008948	95.53	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	95.52	gold quality
intestine	UBERON:0000160	95.52	gold quality
gall bladder	UBERON:0002110	95.43	gold quality
left coronary artery	UBERON:0001626	95.38	gold quality
colon	UBERON:0001155	95.34	gold quality
cortical plate	UBERON:0005343	95.30	gold quality
large intestine	UBERON:0000059	95.27	gold quality
caecum	UBERON:0001153	95.26	gold quality
pylorus	UBERON:0001166	95.23	gold quality
bone element	UBERON:0001474	95.19	gold quality
urinary bladder	UBERON:0001255	95.18	gold quality
female reproductive system	UBERON:0000474	95.14	gold quality
gastrocnemius	UBERON:0001388	95.14	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-CURD-89	no	1523.32
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 159 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Cerebellum	tissue	60.4	high
Bone marrow	tissue	54.5	high
Thymus	tissue	53.4
Retina	tissue	41.6
Tonsil	tissue	41.3	high
Tongue	tissue	40.8
Liver	tissue	40.1	medium
Lymph node	tissue	39.9	high
Skeletal muscle	tissue	37.6	high
Stomach 1	tissue	36.7	high
Corpus callosum	tissue	36.0
Olfactory bulb	tissue	36.0
Putamen	tissue	34.1
Parathyroid gland	tissue	33.9	high
Skin 1	tissue	33.0	high
Liver	tissue	32.7	medium
Spleen	tissue	32.5	medium
Thyroid gland	tissue	31.7	high
Periaqueductal gray	tissue	31.7
Urinary bladder	tissue	31.6	high
Septum	tissue	31.5
Cerebral cortex	tissue	31.4	high
Somatosensory cortex	tissue	31.4
Occipital cortex	tissue	31.2
Amygdala	tissue	31.1
Retrosplenial cortex	tissue	30.2
Rectum	tissue	30.1	high
Hippocampal formation	tissue	30.0
Entorhinal cortex	tissue	30.0
Vagina	tissue	29.9	high
Spinal cord	tissue	29.7
Appendix	tissue	29.7	medium
Prefrontal cortex	tissue	29.6
Adipose tissue	tissue	29.3	high
Substantia nigra	tissue	29.0
Motor cortex	tissue	28.9
Retrosplenial and cingulate cortex	tissue	28.9
Thalamus	tissue	28.7
Kidney	tissue	28.7	high
Ventral forebrain	tissue	28.6
Medulla oblongata	tissue	28.5
Superior colliculi	tissue	28.5
Temporal cortex	tissue	28.3
Basal ganglia	tissue	28.2	high
Hypothalamus	tissue	28.2
Duodenum	tissue	28.2	high
Midbrain	tissue	27.9
Insular cortex	tissue	27.8
Pons	tissue	27.1
Small intestine	tissue	27.1	high
Colon	tissue	27.0	high
Breast	tissue	26.8	high
Pituitary gland	tissue	26.7
Esophagus	tissue	26.7	high
Lung	tissue	26.6	high
Salivary gland	tissue	26.4	high
Testis	tissue	26.0	high
Choroid plexus	tissue	25.6
Choroid plexus	tissue	25.1
Placenta	tissue	24.8	medium

Brain sub-regions (HPA Brain Atlas): detected in 384; highest nTPM — Cerebellar cortex (44.3), Flocculonodular lobe (40.5), Vermis (37.8), White matter (36.0), Area striata (white matter) (34.9).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting SLTM by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 41 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-8087	99.90	69.55	1351
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-4802-3P	99.72	70.13	1273
HSA-MIR-4465	99.71	72.56	2096
HSA-MIR-29B-2-5P	99.67	68.98	1726
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-1290	99.59	69.90	2079
HSA-MIR-513C-5P	99.50	68.42	1730
HSA-MIR-514B-5P	99.50	68.19	1766
HSA-MIR-4325	99.49	72.20	1342
HSA-MIR-147B-5P	99.45	70.62	2432
HSA-MIR-519D-5P	99.41	69.30	2057
HSA-MIR-548B-3P	99.38	67.26	1000
HSA-MIR-7151-5P	99.37	67.82	613
HSA-MIR-377-3P	99.37	70.18	1905

Functional genomics

gnomAD constraint: pLI 1, LOEUF 0.443, missense Z 2.85 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000380516 splits into 3 regions with different missense tolerance; 1 is missense-constrained (≈3% of the expected missense variation). Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
15:58,880,002–58,899,705	776 / 962.2	0.81	no
15:58,899,706–58,899,811	11 / 42.3	0.26	yes (p 1.5e-06)
15:58,899,812–58,933,565	268 / 284.3	0.94	no

ClinGen dosage: haploinsufficiency 0 (no evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 11)

• Inhibition of a Chromatin and Transcription Modulator, SLTM, Increases HIV-1 Reactivation Identified by a CRISPR Inhibition Screen. (PMID:35730977)
• Plexin-B3 expression stimulates MET signaling, breast cancer stem cell specification, and lung metastasis. (PMID:36857181)
• Circular RNA SLTM as a miR-421-competing endogenous RNA to mediate HMGB2 expression stimulates apoptosis and inflammation in arthritic chondrocytes. (PMID:36935520)
• Long noncoding RNA FTX promotes epithelial-mesenchymal transition of epithelial ovarian cancer through modulating miR-7515/TPD52 and activating Met/Akt/mTOR. (PMID:37140169)
• Lack of correlation between MET and PD-L1 expression in non-small cell lung cancer revealed by comparative study of matched biopsies and surgical resection samples. (PMID:37150140)
• A DNA-PK phosphorylation site on MET regulates its signaling interface with the DNA damage response. (PMID:37188738)
• Impact of SMAD2 and MET Expression on Lymph Node Metastasis of HER2-positive Gastric Cancer Cells. (PMID:37772583)
• SPOP promotes CREB5 ubiquitination to inhibit MET signaling in liver cancer. (PMID:37996058)
• MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling. (PMID:38110666)
• Deubiquitinase BRCC3 promotes the migration, invasion and EMT progression of colon adenocarcinoma by stabilizing MET expression. (PMID:38470543)
• circSLTM knockdown attenuates chondrocyte inflammation, apoptosis and ECM degradation in osteoarthritis by regulating the miR-515-5p/VAPB axis. (PMID:38981227)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	sltm	ENSDARG00000052728
mus_musculus	Sltm	ENSMUSG00000032212
rattus_norvegicus	Sltm	ENSRNOG00000054446
drosophila_melanogaster	Saf-B	FBGN0039229
caenorhabditis_elegans	phm-2	WBGENE00009314

Paralogs (2): SAFB2 (ENSG00000130254), SAFB (ENSG00000160633)

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pongo abelii	Q5NVN8	99.4%	Diamond
Macaca fascicularis	Q95KI0	97.9%	Diamond
Bos taurus	A6QPR6	96.4%	Diamond
Xenopus laevis	A4F5G6	86.9%	Diamond
Xenopus tropicalis	Q66JB7	86.9%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
MIR2116	ncRNA	100313886
MYO1E	protein-coding	4643
RNF111	protein-coding	54778
CCNB2	protein-coding	9133
MINDY2-DT	ncRNA	101928725
MINDY2	protein-coding	54629

Protein

Protein identifiers

SAFB-like transcription modulator — Q9NWH9 (reviewed: Q9NWH9)

Alternative names: Modulator of estrogen-induced transcription

All UniProt accessions (12): Q9NWH9, H0YKH2, H0YKU6, H0YL55, H0YLE6, H0YLW7, H0YMM0, H0YMR6, H0YMW8, H0YNF3, H7BXE3, H7C3F4

UniProt curated annotations — full annotation on UniProt →

Function. When overexpressed, acts as a general inhibitor of transcription that eventually leads to apoptosis.

Subcellular location. Nucleus.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NWH9-1	1	yes
Q9NWH9-3	2

RefSeq proteins (2): NP_001013865, NP_079031* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR003034	SAP_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR035979	RBD_domain_sf	Homologous_superfamily
IPR036361	SAP_dom_sf	Homologous_superfamily
IPR051738	SAFB_related	Family

Pfam: PF00076, PF02037

UniProt features (65 total): modified residue 26, compositionally biased region 21, region of interest 4, cross-link 4, sequence conflict 3, domain 2, initiator methionine 1, chain 1, splice variant 1, sequence variant 1, coiled-coil region 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NWH9-F1	52.38	0.11

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Transferases, Kinases, Tyr protein kinases, Transporters, Accessory Factors Involved in Transport, Predicted membrane proteins, Predicted secreted proteins, Predicted intracellular proteins, Plasma proteins, RAS pathway related proteins, Cancer-related genes, Candidate cancer biomarkers, Mutated cancer genes, Disease related genes, FDA approved drug targets, Biotech drugs, Small molecule drugs, Human disease related genes, Ear disease

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): plasma membrane; cytosol

Antibody reliability (HPA): IH approved · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (30)

Type	Positions
N-acetylalanine	2
Phosphoserine	93, 97, 139, 144, 289, 421, 550, 551, 553, 748, 789, 800, 815, 909, 923, 929, 944, 998, 1002, 1014, 1019, 1021
N6-acetyllysine	401, 1024
Omega-n-methylarginine	1017
Glycyl lysine isopeptide (lys-gly) (interchain with g-cter in sumo2)	500, 884, 1024, 1027

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 660 (showing top): GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, CHOI_ATL_ACUTE_STAGE, GOBP_ENDOTHELIAL_CELL_DEVELOPMENT, GOBP_HEPATICOBILIARY_SYSTEM_DEVELOPMENT, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_REGULATION_OF_AUTOPHAGY, WANG_CLIM2_TARGETS_UP, GOBP_POSITIVE_REGULATION_OF_ENDOTHELIAL_CELL_CHEMOTAXIS, GOBP_CELL_CHEMOTAXIS, MIDORIKAWA_AMPLIFIED_IN_LIVER_CANCER, GOBP_EPITHELIAL_CELL_DEVELOPMENT, PAL_PRMT5_TARGETS_UP, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOCC_CELL_SURFACE, GOBP_NEUROGENESIS

GO Biological Process (2): DNA-templated transcription (GO:0006351), apoptotic process (GO:0006915)

GO Molecular Function (3): RNA binding (GO:0003723), nucleic acid binding (GO:0003676), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), nuclear body (GO:0016604)

GO top-level categories

12 GO namespaces:

Category	Terms
binding	2
gene expression	1
RNA biosynthetic process	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
nucleic acid binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
nucleoplasm	1
intracellular membraneless organelle	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 3 of 8 annotations. The rest are phylogenetic / computational / electronic (IEA).

3 experimentally-supported GO terms:

GO term	NS	Evidence
nuclear body	CC	direct assay
nucleoplasm	CC	direct assay
RNA binding	MF	high-throughput assay

Protein interactions and networks

STRING

showing 15 of 1,358 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLTM	PARD3B	Q8TEW8	366
SLTM	COMMD2	Q86X83	352
SLTM	ZNF304	Q9HCX3	344
SLTM	CSTF2T	Q9H0L4	333
SLTM	BUD13	Q9BRD0	320
SLTM	ZFP90	Q8TF47	317
SLTM	VMA12	Q8N511	308
SLTM	ERMP1	Q7Z2K6	304
SLTM	ZNF214	Q9UL59	303
SLTM	SF3B4	Q15427	299
SLTM	WDR81	Q562E7	298
SLTM	TRA2A	Q13595	296
SLTM	LARP4	Q71RC2	296
SLTM	TMEM178A	Q8NBL3	291
SLTM	NCBP2	P52298	290

IntAct

Human interaction partners of SLTM in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

9 partners by confidence:

Partner	Interaction type	MIscore	Records
MCC	physical association	0.560	3
CYLC1	physical association	0.400	1
DRC2	physical association	0.400	1
JAKMIP2	physical association	0.400	1
MBL2	physical association	0.400	1
NELL1	physical association	0.400	1
PRKACA	physical association	0.400	1
REV3L	physical association	0.400	1
SMC1B	physical association	0.400	1

BioGRID (189 interactions; top human partners by supporting records): FGL1 (Affinity Capture-MS; 3 records), MYC (Affinity Capture-MS; 3 records), ANLN (Affinity Capture-MS; 2 records), APOBEC3D (Affinity Capture-MS; 2 records), CEP19 (Proximity Label-MS; 2 records), ESR2 (Affinity Capture-MS; 2 records), EZH2 (Affinity Capture-MS; 2 records), GGPS1 (Affinity Capture-MS; 2 records), IKZF5 (Affinity Capture-MS; 2 records), LTBR (Affinity Capture-MS; 2 records), SNRNP70 (Affinity Capture-MS; 2 records), STK4 (Affinity Capture-MS; 2 records), SUZ12 (Affinity Capture-MS; 2 records), ZC3H18 (Affinity Capture-MS; 2 records), AATF (Affinity Capture-MS)

Ligand–receptor pairs (CellPhoneDB) (1)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

1 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
MET

Disease & clinical

Cancer significance

From CIViC — curated cancer-variant interpretation:

Mesenchymal Epithelial Transition MET is a prototypical receptor tyrosine kinase. Its ligand is Hepatocyte Growth Factor (HGF). MET alterations are drivers of human cancer. Amplification and resulting overexpression has been reported in several cancers, and make the receptor’s activity independent of HGF. Gene fusions also decouple kinase activity from the cell membrane and render it constitutively active. Finally, exclusion of the juxtamembrane (JM) domain of the kinase by ““skipping”” of exon 14 activates the kinase. FDA-approved selective MET inhibitors, including tepotinib and capmatinib, have shown efficacy in cancers with exon 14 skipping mutations or MET amplification.

From intOGen — cancer-driver classification: activating (oncogene-like) across 7 cancer types — CCRCC, LGGNOS, LUAD, NSCLC, OS, PRCC, RCC.

intOGen’s role is a computational inference from cohort mutation patterns and may diverge from the gene’s curated/literature role; read it alongside the evidence above.

Genetic variants

Variant evidence for SLTM: 5,104 ClinVar records (8 pathogenic / likely pathogenic); 8 CIViC cancer variants; 26 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

5,104 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	5
Likely pathogenic	3
Uncertain significance	2707
Likely benign	1232
Benign	130

Top pathogenic / likely-pathogenic (8)

Showing all 8 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
183686	NM_000245.4(MET):c.2521T>G (p.Phe841Val)	Pathogenic	criteria provided, single submitter	2
376126	NM_000245.4(MET):c.3749T>C (p.Met1250Thr)	Likely pathogenic	criteria provided, single submitter	2
3384110	NM_000245.4(MET):c.3503T>G (p.Phe1168Cys)	Likely pathogenic	criteria provided, single submitter	1
13882	NM_000245.4(MET):c.3562G>T (p.Val1188Leu)	Pathogenic	no assertion criteria provided	1
13889	NM_000245.4(MET):c.3750G>A (p.Met1250Ile)	Pathogenic	no assertion criteria provided	1
13890	NM_000245.4(MET):c.3731A>G (p.Lys1244Arg)	Pathogenic	no assertion criteria provided	1
998144	NM_000245.4(MET):c.2855del (p.Phe952fs)	Pathogenic	no assertion criteria provided	1
617857	NM_024755.4(SLTM):c.2600C>A (p.Pro867His)	Likely pathogenic	no assertion criteria provided	1

Per-variant reference — Sugi Variant

Explore SLTM’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 25 predictions of 3,551):

Position(s)	Effect	Δscore	Sites
15:58883624–58883625	donor_loss	1.0000	5
15:58883787–58883788	acceptor_loss	1.0000	5
15:58886974	donor_loss	1.0000	2
15:58887120	acceptor_loss	1.0000	3
15:58887129	acceptor_gain	1.0000
15:58888383–58888384	donor_loss	1.0000	4
15:58888557	acceptor_gain	1.0000
15:58889429	donor_loss	1.0000	2
15:58889464	donor_gain	1.0000
15:58889555	acceptor_gain	1.0000

AlphaMissense

2,225 missense substitutions predicted likely pathogenic (of 6,835 scored), across 571 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M610	9	0.912	0.999
M432	9	0.910	0.998
F404	8	0.990	0.999
H451	8	0.979	0.997
D399	8	0.978	0.997
D258	8	0.966	0.988
F607	8	0.966	0.999
D251	8	0.964	0.995
D256	8	0.950	0.990
D260	8	0.948	0.990
D261	8	0.933	0.979
D29	8	0.882	0.986
D40	8	0.881	0.981
N385	8	0.861	0.993
S389	8	0.858	0.992
D463	8	0.838	0.958
C426	7	0.997	1.000
W387	7	0.996	1.000
E698	7	0.989	0.998
E685	7	0.986	0.997

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

4 prognostic cancer types:

Cancer	Prognostic	p-value
Pancreatic Adenocarcinoma (TCGA)	unfavorable	6.8e-06
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	2.69e-05
Kidney Renal Clear Cell Carcinoma (validation)	favorable	4.09e-05
Head and Neck Squamous Cell Carcinoma (TCGA)	unfavorable	0.000297

Disease associations

OMIM: gene MIM:620992 | disease phenotypes: MIM:616705 (Deafness, autosomal recessive 97), MIM:620019 (Arthrogryposis, distal, type 11)

GenCC curated gene-disease

6 curated gene-disease records:

Disease	Classification	Inheritance	Records
hereditary papillary renal cell carcinoma	Definitive	Autosomal dominant	3
papillary renal cell carcinoma	Definitive	Autosomal dominant	4
autosomal recessive nonsyndromic hearing loss 97	Strong	Autosomal recessive	2
osteofibrous dysplasia	Supportive	Autosomal dominant	2
hearing loss, autosomal recessive	Supportive	Autosomal recessive
arthrogryposis, distal, IIa 11	Limited	Autosomal dominant	2

ClinGen Gene-Disease Validity

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

3 validity classifications:

Disease	Classification	Inheritance
papillary renal cell carcinoma	Definitive	AD
complex neurodevelopmental disorder	Disputed	AD
nonsyndromic genetic hearing loss	Limited	AR

Mondo (9): hereditary papillary renal cell carcinoma (MONDO:0003789), papillary renal cell carcinoma (MONDO:0017884), autosomal recessive nonsyndromic hearing loss 97 (MONDO:0014739), osteofibrous dysplasia (MONDO:0011806), hearing loss, autosomal recessive (MONDO:0019588), arthrogryposis, distal, IIa 11 (MONDO:0031045), renal cell carcinoma (MONDO:0005086), hereditary neoplastic syndrome (MONDO:0015356), pediatric hepatocellular carcinoma (MONDO:0018055)

Orphanet (3): Renal cell carcinoma (Orphanet:217071), Inherited cancer-predisposing syndrome (Orphanet:140162), Pediatric hepatocellular carcinoma (Orphanet:33402)

HPO phenotypes

30 phenotypes (HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000407	Sensorineural hearing impairment
HP:0000767	Pectus excavatum
HP:0001395	Hepatic fibrosis
HP:0001402	Hepatocellular carcinoma
HP:0001413	Micronodular cirrhosis
HP:0001442	Typified by somatic mosaicism
HP:0001762	Talipes equinovarus
HP:0001838	Rocker bottom foot
HP:0001840	Metatarsus adductus
HP:0001848	Calcaneovalgus deformity
HP:0002013	Vomiting
HP:0002027	Abdominal pain
HP:0002240	Hepatomegaly
HP:0002605	Hepatic necrosis
HP:0002756	Pathologic fracture
HP:0003038	Fibular hypoplasia
HP:0003577	Congenital onset
HP:0003829	Typified by incomplete penetrance
HP:0005864	Pseudoarthrosis
HP:0006077	Absent proximal finger flexion creases
HP:0006254	Elevated circulating alpha-fetoprotein concentration
HP:0006394	Limited pronation/supination of forearm
HP:0006572	Subacute progressive viral hepatitis
HP:0006766	Papillary renal cell carcinoma
HP:0012378	Fatigue
HP:0012385	Camptodactyly
HP:0030242	Portal vein thrombosis
HP:0410019	Epigastric pain

GWAS associations

26 associations:

Study	Trait	p-value
GCST004234_4	HDL cholesterol levels	6e-27
GCST004232_29	HDL cholesterol levels	2e-26
GCST004238_7	Triglyceride levels	3e-18
GCST004237_36	Triglyceride levels	8e-18
GCST007431_64	Lung function (FEV1/FVC)	4e-12
GCST002456_5	PR segment duration	5e-12
GCST90000047_69	Age at first sexual intercourse	4e-10
GCST011349_28	Gamma glutamyl transferase levels	1e-9
GCST90011898_121	Alanine aminotransferase levels	1e-9
GCST004237_15	Triglyceride levels	5e-9
GCST005956_33	Waist-to-hip ratio adjusted for BMI	5e-9
GCST006019_32	Gamma glutamyl transferase levels	5e-9
GCST003818_35	Resting heart rate	7e-9
GCST002216_16	Triglycerides	2e-8
GCST012309_2	Schizophrenia	2e-8
GCST012489_62	Heel bone mineral density x serum urate levels interaction	2e-8
GCST007269_216	Pulse pressure	3e-8
GCST007927_11	Medication use (beta blocking agents)	4e-8
GCST005962_14	Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test)	3e-7
GCST006585_321	Blood protein levels	1e-6
GCST004003_2	Hematocrit	2e-6
GCST006585_1833	Blood protein levels	3e-6
GCST012311_14	Schizophrenia x sex interaction	3e-6
GCST000266_1	Multiple sclerosis (severity)	6e-6
GCST000904_2	Asperger disorder	7e-6
GCST005789_14	Resting heart rate	7e-6

EFO canonical traits (from GWAS)

14 canonical traits:

EFO ID	Trait name
EFO:0004530	triglyceride measurement
EFO:0005095	PR segment
EFO:0004348	hematocrit
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008007	age at assessment
EFO:0008343	sex interaction measurement
EFO:0004532	serum gamma-glutamyl transferase measurement
EFO:0005763	pulse pressure measurement
EFO:0004713	FEV/FVC ratio
EFO:0009929	Beta blocking agent use measurement
EFO:0004531	urate measurement
EFO:0009270	heel bone mineral density
EFO:0009749	age at first sexual intercourse measurement

MeSH disease descriptors

5 disease descriptors:

Descriptor	Name	Tree numbers
D002292	Carcinoma, Renal Cell	C04.557.470.200.025.390; C04.588.945.947.535.160; C12.050.351.937.820.535.160; C12.050.351.968.419.473.160; C12.200.758.820.750.160; C12.200.777.419.473.160; C12.900.820.535.160; C12.950.419.473.160; C12.950.983.535.160
D009386	Neoplastic Syndromes, Hereditary	C04.700; C16.320.700
C564609	Deafness, Autosomal Recessive *(supp.)*
C563276	Osteofibrous Dysplasia *(supp.)*
C563787	Tibia, Bowing of, with Pseudarthrosis and Pectus Excavatum *(supp.)*

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523469 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 11,799 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

1 molecule by phase:

Molecule	Name	Phase	Patents
CHEMBL2105717	CABOZANTINIB	4	11,799

Clinical evidence (CIViC)

Drug × variant × indication, from 74 curated evidence items; also 2 prognostic, 1 diagnostic, 1 functional. CIViC evidence level: A (validated) → B (clinical) → C (case study) → D (preclinical) → E (inferential).

showing 30 of 47 predictive associations by evidence level:

Variant	Therapy	Indication	Effect	Level	CIViC
MET Exon 14 Skipping Mutation	Tepotinib	Lung Non-small Cell Carcinoma	Sensitivity/Response	CIViC A	EID11766 +3
MET Exon 14 Skipping Mutation	Capmatinib	Lung Non-small Cell Carcinoma	Sensitivity/Response	CIViC A	EID8847 +2
MET Amplification	Crizotinib	Lung Non-small Cell Carcinoma	Sensitivity/Response	CIViC B	EID7502 +4
MET Exon 14 Skipping Mutation	Crizotinib	Lung Non-small Cell Carcinoma	Sensitivity/Response	CIViC B	EID11416 +3
MET Amplification	Crizotinib	Gastrointestinal System Cancer	Sensitivity/Response	CIViC B	EID11454
MET Amplification	Savolitinib	Stomach Cancer	Sensitivity/Response	CIViC B	EID7729
MET Amplification	Capmatinib	Lung Non-small Cell Carcinoma	Sensitivity/Response	CIViC B	EID8849
MET Exon 14 Skipping Mutation	Crizotinib	Stomach Cancer	Sensitivity/Response	CIViC B	EID11377
MET Exon 14 Skipping Mutation	SAIT301	Stomach Cancer	Sensitivity/Response	CIViC B	EID11378
MET Exon 14 Skipping Mutation	Crizotinib	Colorectal Cancer	Sensitivity/Response	CIViC B	EID11379
MET Exon 14 Skipping Mutation	SAIT301	Colorectal Cancer	Sensitivity/Response	CIViC B	EID11380
MET Mutation	Foretinib	Papillary Renal Cell Carcinoma	Sensitivity/Response	CIViC B	EID796
MET Overexpression	Rilotumumab	Gastric Adenocarcinoma	Sensitivity/Response	CIViC B	EID5835
MET Overexpression	Vemurafenib	Skin Melanoma	Resistance	CIViC B	EID1581 +1
MET Exon 14 Skipping Mutation	Crizotinib	Lung Adenocarcinoma	Sensitivity/Response	CIViC C	EID11384 +8
MET Exon 14 Skipping Mutation	Tepotinib	Lung Adenocarcinoma	Sensitivity/Response	CIViC C	EID11464 +3
MET Amplification	Crizotinib	Lung Adenocarcinoma	Sensitivity/Response	CIViC C	EID11383 +2
MET Exon 14 Skipping Mutation	Capmatinib	Lung Adenocarcinoma	Sensitivity/Response	CIViC C	EID11417 +1
MET Amplification	Crizotinib	Glioblastoma	Sensitivity/Response	CIViC C	EID1565
MET Amplification	Crizotinib + Vemurafenib	Colorectal Cancer	Sensitivity/Response	CIViC C	EID1588
MET Amplification	Crizotinib	Cancer	Sensitivity/Response	CIViC C	EID1714
MET Amplification	Onartuzumab	Gastric Adenocarcinoma	Sensitivity/Response	CIViC C	EID689
MET Amplification	Crizotinib	Lung Squamous Cell Carcinoma	Sensitivity/Response	CIViC C	EID890
MET Amplification AND MET Splice Site (c.3028G>A)	Crizotinib	Lung Non-small Cell Carcinoma	Sensitivity/Response	CIViC C	EID1095
MET D1228V	Cabozantinib	Lung Non-small Cell Carcinoma	Sensitivity/Response	CIViC C	EID1864
MET Exon 14 Skipping Mutation	Cabozantinib	Lung Adenocarcinoma	Sensitivity/Response	CIViC C	EID11400
MET Exon 14 Skipping Mutation	Crizotinib + Cabozantinib	Lung Adenocarcinoma	Sensitivity/Response	CIViC C	EID11410
MET Exon 14 Skipping Mutation	Savolitinib	Lung Adenocarcinoma	Sensitivity/Response	CIViC C	EID11474
MET Exon 14 Skipping Mutation	Carboplatin/Pemetrexed Regimen + Pembrolizumab	Lung Adenocarcinoma	Sensitivity/Response	CIViC C	EID11487
MET Exon 14 Skipping Mutation	Crizotinib	Histiocytic And Dendritic Cell Cancer	Sensitivity/Response	CIViC C	EID7796

CIViC column: a representative evidence item (EID); +N = additional CIViC items supporting the same association.

CIViC curated variants (8)

Named clinical variants curated in CIViC for this gene (the catalogue beneath the predictive evidence above):

Amplification (transcript amplification), R1004G (missense variant), Mutation (transcription variant,gain of function variant), Exon 14 Skipping Mutation (exon loss variant), Splice Site (c.3028G>A) (splice donor variant), Overexpression, D1228N (missense variant), D1228V (missense variant).

PharmGKB: 1 entry (CPIC guideline: no)

PharmGKB variant annotations

Per-publication pharmacogenomic findings for this gene (significant associations).

2 published findings:

Variant	Drug(s)	Category	Finding	PMID
rs40239		Other	Genotypes AG + GG is associated with increased overall survival in people with Stomach Neoplasms as compared to genotype AA.	PMID:25203738
rs40239		Other	Genotypes AG + GG is associated with increased overall survival in men Stomach Neoplasms as compared to genotype AA.	PMID:25203738

Binding affinities (BindingDB)

1 measured of 3 human assays (3 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEBI:72317	IC50	14 nM

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.89	IC50	1.3	nM	CABOZANTINIB

PubChem BioAssay actives

1 with measured affinity, of 15 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
Cabozantinib	1895682: Inhibition of human recombinant full length c-Met in presence of ATP by alphascreen assay	ic50	0.0013	uM

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases methylation, increases expression, affects cotreatment, decreases expression	4
sodium arsenite	decreases expression, increases expression	2
methacrylaldehyde	affects cotreatment, increases oxidation, decreases expression, increases abundance	2
Acrolein	affects cotreatment, increases oxidation, decreases expression, increases abundance	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, decreases expression	2
Ozone	affects cotreatment, increases oxidation, decreases expression, increases abundance	2
FR900359	affects phosphorylation	1
TAK-243	decreases sumoylation	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
deoxynivalenol	increases expression	1
potassium perchlorate	increases expression	1
titanium dioxide	decreases methylation	1
butyraldehyde	decreases expression	1
bleomycetin	decreases expression	1
benzo(e)pyrene	increases methylation	1
coumarin	decreases phosphorylation	1
nivalenol	increases expression	1
celastrol	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
gedunin	decreases expression	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
bisphenol B	increases expression	1
bisphenol S	affects cotreatment, decreases expression	1
LDN 193189	decreases expression, affects cotreatment	1
Rosiglitazone	decreases reaction, increases expression	1
Pioglitazone	decreases reaction, increases expression	1
Sunitinib	increases expression	1
Troglitazone	increases expression, affects cotreatment, decreases expression, decreases reaction	1

ChEMBL screening assays

14 unique, capped per target: 14 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4341402	Binding	Binding affinity to SLTM in human A549 cells lysates grown on SILAC media at 10 uM incubated for 1 hr by LC-MS/MS analysis relative to untreated control	Profiling withanolide A for therapeutic targets in neurodegenerative diseases. — *Bioorg Med Chem*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 327 trials:

NCT	Phase	Status	Title
NCT00414765	Phase 4	COMPLETED	Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
NCT00777504	Phase 4	UNKNOWN	Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
NCT00930345	Phase 4	TERMINATED	Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
NCT01206764	Phase 4	COMPLETED	A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
NCT01266837	Phase 4	COMPLETED	Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
NCT02056587	Phase 4	COMPLETED	Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment
NCT02338570	Phase 4	TERMINATED	Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)
NCT02596035	Phase 4	COMPLETED	An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
NCT02982954	Phase 4	COMPLETED	A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
NCT05949424	Phase 4	UNKNOWN	OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
NCT07028125	Phase 4	RECRUITING	Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
NCT07405086	Phase 4	RECRUITING	Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
NCT05043090	Phase 3	ACTIVE_NOT_RECRUITING	Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT06146777	Phase 3	NOT_YET_RECRUITING	Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
NCT00033904	Phase 3	COMPLETED	Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
NCT00126178	Phase 3	TERMINATED	Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
NCT00291369	Phase 3	COMPLETED	Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis
NCT00410124	Phase 3	COMPLETED	RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
NCT00474786	Phase 3	COMPLETED	Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
NCT00478114	Phase 3	COMPLETED	Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
NCT00606632	Phase 3	COMPLETED	Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
NCT00606866	Phase 3	COMPLETED	MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma
NCT00631371	Phase 3	COMPLETED	Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
NCT00732914	Phase 3	COMPLETED	Sequential Study to Treat Renal Cell Carcinoma
NCT00869011	Phase 3	UNKNOWN	Exercise for Patients With Renal Cell Cancer Receiving Sunitinib
NCT00930033	Phase 3	COMPLETED	Clinical Trial to Assess the Importance of Nephrectomy
NCT01030783	Phase 3	COMPLETED	A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
NCT01076010	Phase 3	COMPLETED	An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
NCT01198158	Phase 3	TERMINATED	Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
NCT01223027	Phase 3	COMPLETED	Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
NCT01224288	Phase 3	ACTIVE_NOT_RECRUITING	Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
NCT01235962	Phase 3	COMPLETED	A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
NCT01265810	Phase 3	COMPLETED	Caphosol in Oral Mucositis Due to Targeted Therapy
NCT01265901	Phase 3	COMPLETED	IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
NCT01481870	Phase 3	UNKNOWN	Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma
NCT01582672	Phase 3	TERMINATED	Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
NCT01613846	Phase 3	COMPLETED	Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
NCT01762592	Phase 3	WITHDRAWN	REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
NCT01865747	Phase 3	COMPLETED	A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
NCT02231749	Phase 3	COMPLETED	Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
NCT02420821	Phase 3	COMPLETED	A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
NCT02811861	Phase 3	ACTIVE_NOT_RECRUITING	Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02853331	Phase 3	COMPLETED	Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
NCT03024996	Phase 3	TERMINATED	A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
NCT03055013	Phase 3	ACTIVE_NOT_RECRUITING	Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03141177	Phase 3	COMPLETED	A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03142334	Phase 3	COMPLETED	Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
NCT03260894	Phase 3	COMPLETED	Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
NCT03288532	Phase 3	RECRUITING	Renal Adjuvant MultiPle Arm Randomised Trial
NCT03408652	Phase 3	TERMINATED	Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies
NCT03592472	Phase 3	RECRUITING	A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
NCT03693573	Phase 3	WITHDRAWN	A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
NCT03729245	Phase 3	TERMINATED	A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator’s Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
NCT03873402	Phase 3	ACTIVE_NOT_RECRUITING	A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
NCT03937219	Phase 3	ACTIVE_NOT_RECRUITING	Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT04510597	Phase 3	RECRUITING	Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04588246	Phase 3	TERMINATED	Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NCT04764487	Phase 3	UNKNOWN	A Web-mediated Follow-up With the Web-application KidneyPRO Versus Standard Follow-up for Patients With Advanced Renal Cell Carcinoma Treated With Axitinib/Pembrolizumab in First Line
NCT04987203	Phase 3	COMPLETED	Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
NCT05078047	Phase 3	ACTIVE_NOT_RECRUITING	Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for SLTM across ~30M SureChEMBL compounds — explore on Sugi Predict.